Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
- 1 February 2015
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 135 (2) , 551-553.e3
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibitionNature Medicine, 2014
- Activated STING in a Vascular and Pulmonary SyndromeNew England Journal of Medicine, 2014
- Fatal combined immunodeficiency associated with heterozygous mutation in STAT1Journal of Allergy and Clinical Immunology, 2014
- New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central EuropeJournal of Medical Genetics, 2013
- Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasisCurrent Opinion in Allergy and Clinical Immunology, 2012
- Chronic Mucocutaneous Candidiasis Caused by a Gain-of-Function Mutation in the STAT1 DNA-Binding DomainThe Journal of Immunology, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous CandidiasisNew England Journal of Medicine, 2011
- Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasisJournal of Experimental Medicine, 2011
- Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophyJournal of Allergy and Clinical Immunology, 2010